Sun Pharma Corporate Overview

Key Financials Q4 & FY21 SUN PHARMA Q4 FY21 Q4 FY20 CHANGE FY21 FY20 (All Figures in Rs. Mn) CHANGE Gross Sales 84,314 80,780 4.4% 331,392 323,252 2.5% Gross Profit 61,906 57,732 7.2% 244,491 230,947 5.9% Gross Margin 73.4% 71.5% 73.8% 71.4% EBITDA 19,568 12,561 55.8% 81,324 64,774 25.5% EBITDA Margin 23.2% 15.5% 24.5% 20.0% Net Profit 8,942 3,998 123.6% 29,038 37,649 -22.9% Net margin 10.6% 4.9% 8.8% 11.6% # Net Profit (Adjusted) 13,430 6,605 103.3% 59,317' # 40,256 47.4% Net margin (Adjusted) 15.9% 8.2% 17.9% 12.5% R&D 5,571 5,360 3.9% 21,499 19,736 8.9% R&D as % of Net Sales 6.6% 6.6% 6.5% 6.1% EPS (Diluted) INR 3.7 1.7 123.6% 12.1 15.7 -22.9% # EPS (Diluted) INR (Adjusted) 5.6 2.8 103.3% 24.77 16.8 47.4% # Q4 FY21 - Adjusted for 4.5 bn provision (related to Taro US DoJ settlement Rs. 5.8 bn, provision related to UK Citalopram case Rs. 0.9 bn & provision related to deferred tax gain Rs. 1.2 bn. Taro provisions are adjusted for minority interest) # FY21 - Adjusted for Rs. 30.3 bn provision (related to Taro US - DOJ & MDL settlement Rs. 42.2, provision related to UK Citalopram case Rs. 0.9 bn & provision related to deferred tax gain Rs. 4.1 bn. Taro provisions are adjusted for minority interest) # Q4FY20 & FY20 - Adjusted for Rs. 2.6 bn provision (related to Dusa US DoJ settlement of Rs. 1.6 bn and Indirect Tax provision of Rs. 1.0 bn in India) © Sun Pharmaceutical Industries Limited. All Rights Reserved. 48

View entire presentation